IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1
James Lee(Rutgers, The State University of New Jersey), Austin Gurney(OncoMed (United States)), Jessica Foster(PDL BioPharma (United States)), Daniel G. Yansura, Wei-Hsien Ho(PDL BioPharma (United States)), Richard Vandlen(PDL BioPharma (United States)), Miko Maruoka(PDL BioPharma (United States)), William I. Wood(Genesys (United States)), Audrey D. Goddard(PDL BioPharma (United States)), Racquel Corpuz(PDL BioPharma (United States)), Daryl T. Baldwin(PDL BioPharma (United States))
Cited by 410
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.7k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
|Nature Genetics|2017|1.5k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k